Breaking News, Collaborations & Alliances

Affimed, MD Anderson Form Immuno-Oncology Collaboration

Agreement brings together MD Anderson’s natural killer cell and Affimed’s antibody-based technologies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Affimed N.V., a clinical stage biopharma company focused on discovering and developing highly targeted cancer immunotherapies, and The University of Texas MD Anderson Cancer Center, have formed an exclusive strategic clinical development and commercialization collaboration to evaluate Affimed’s TandAb technology in combination with MD Anderson’s natural killer cell (NK) product. NK-cells are white blood cells, which monitor the body for infected and cancerous cells. The technology to grow NK-...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters